DENVER, CO--(Marketwire - July 26, 2012) - Since releasing their RTx suite of high-level software tools for radiotherapy planning and assessment earlier this year, Mirada Medical has witnessed accelerating licensing sales worldwide including: the Gray Institute for Radiation Oncology and Biology, Moffitt Cancer Center, and Kettering Health Network. At this year's AAPM meeting (American Association of Physicists in Medicine, booth 1345), being held this week in Charlotte, NC, Mirada is introducing enhancements to RTx that take full advantage of the company's powerful deformable registration and further its notoriety for highly efficient workflows.
"Imaging plays a crucial role in our clinical research and trials and our projects are producing massive quantities of imaging data." said Professor Gillies McKenna, Director of the Gray Institute. "Mirada software provides us with an extensive set of tools to provide in-depth analysis of this valuable data and efficient time-saving features for planning," McKenna added.
Mirada Medical is recognized for its leadership development of fast and accurate image fusion and deformable registration technology, for more than a decade. The company's algorithms are modality specific and yield the fast, highly accurate results that are essential for getting the most from the powerful software tools in the RTx suite. These include: dose warping and summation, atlas-based auto-contouring, deformable fusion of sequence MR, PET and SPECT and single click contour warping for rapid adaptive planning. The latest versions of all of these powerful planning and assessment tools will be unveiled in the Mirada exhibit at AAPM.
"The laborious task of manually contouring an RT plan can take hours," stated Timor Kadir, Chief Science and Technology Officer for Mirada Medical. "RTx provides automated contour warping from a previous plan or atlas significantly speeding up the process." according to Kadir.
About Mirada Medical Ltd
Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada's products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.
The company specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention. Mirada's advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world's leading healthcare companies.
Mirada Medical was originally spun out of the University of Oxford. The company's technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada's world headquarters in Oxford, England.
Mirada Medical, XD3, Casemeeting, Caseaccess and RTx are all trademarks of Mirada Medical Ltd.
Mirada Medical AAPM release in pdf : http://hugin.info/143183/R/1629709/522070.pdf